Protalix BioTherapeutics Inc. announced a reverse stock split of its shares at a 1-for-10 ratio, effective Dec. 19.
The Israeli company hopes to regain compliance with the New York Stock Exchange's price listing requirements through the reverse split.
Protalix will reduce common authorized shares
American Stock Transfer & Trust Co. is the transfer agent for the reverse stock split.
Protalix is a biopharmaceutical company that develops therapies for genetic diseases.